References

Ashok, M. Analysis of HER2 Testing in Breast Cancer; Disparities, cost effectiveness, and patterns of care [dissertation thesis]. Atlanta, GA: Georgia Institute of Technology; 2009.

Bond™ Oracle™ HER2 IHC System for Leica BOND-MAX System [Instructions for use]. Wetzlar, Germany: Leica Microsystems; 2014.

Cancer.net web site. Follow-up Care for Breast Cancer. December 7, 2015. Available at: http://www.cancer.net/publications-and-resources/what-know-ascos-guidelines/what-know-ascos-guideline-follow-care-breast-cancer. Accessed May 15, 2016.

CAP Commission on Laboratory Accreditation - Laboratory Accreditation Program. Anatomic Pathology Accreditation Checklist. Northfield, IL: July 2015.

Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989; 63:181-187.

Clinical and Laboratory Standards Institute. Quality Assurance for Design Control and Implementation of Immunohistochemistry Assays. 2nd ed. CLSI document I/LA28-A2. Wayne, PA: CLSI; 2011.

Clinical and Laboratory Standards Institute. Quality Assurance for Immunocytochemistry. 4th ed. CLSI document MM4-A. Wayne, PA: CLSI; 1999.

Fisher ER, Sass R, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol No 4). X. Discriminants for tenth year treatment failure. Cancer. 1984; 53 (3 Suppl):712-723. Available at: http://www.ncbi.nlm.nih.gov/pubmed/6692274. Accessed May 15, 2016.

Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic Factors in Breast Cancer College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. July 2000; 124(7):966-978. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10888772. Accessed May 15, 2016.

Fitzgibbons PL, Dillon DA, Alsabeh R, et al. Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. Northfield, IL: College of American Pathologists: December 2014 [web posting]. Available at: http://www.cap.org/ShowProperty?nodePath=/UCMCon/Contribution%20Folders/WebContent/pdf/cp-breast-biomarker-template-14.pdf. Accessed May 15, 2016.

Genetech; FDA submission, STN: 103792\5008\0. Trastuzumab, Herceptin®. Submission for final approval, April 2, 2001.

Hammond MEH, Hayes DF, Wolff AC, et al. American Society for Clinical Oncology/College of American Pathologists, Guidelines Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Arch Pathol Lab Med. June 2010; 134:48-72. Available at: http://www.archivesofpathology.org/doi/pdf/10.1043/1543-2165-134.7.e48. Accessed May 15, 2016.

Hardy LB, Fitzgibbons PL, Goldsmith JD, et al. Immunohistochemistry Validation Procedures and Practices: A College of American Pathologists Survey of 727 Laboratories. Arch Pathol Lab Med. January 2013; 137(1):19-25. Available at: http://www.archivesofpathology.org/doi/full/10.5858/arpa.2011-0676-CP. Accessed May 15, 2016.

Hartman AK, Gorman BK, Chakraborty S, et al. Determination of HER2/Neu Status. Arch Pathol Lab Med. Apri 2014; 138:553-558. Available at: http://www.archivesofpathology.org/doi/pdf/10.5858/arpa.2013-0314-SA. Accessed May 15, 2016.

Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; 17(5):1474-1481.

Leitner SP, Swern AS, Weinberger D, et al. Predictors of Recurrence for Patients with Small (One Centimeter or Less) Localized Breast Cancer (T1a,b N0 M0). Cancer. 1995; 76(11):2266-2274. Available at: http://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19951201)76:11%3C2266::AID-CNCR2820761114%3E3.0.CO;2-T/pdf. Accessed May 15, 2016.

Nakhleh RE, Fitzgibbons PL. Quality Management in Anatomic Pathology: Promoting Patient Safety through Systems Improvement and Error Reduction. Northfield, IL: College of American Pathologists; 2005

Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Ongogene. 1996; 13(1):63-72.

Tinnemans JG, Wobbes T, Holland R, et al. Treatment and survival of female patients with non palpable breast carcinoma. Ann Surg. 1989; 209:249-253.

Wolf AC, Hammond ME, Hicks DG, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 2013; 31:3997-4013. Available at: http://jco.ascopubs.org/content/31/31/3997.full. Accessed May 15, 2016.

Wolf AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 131:118-145.

Yeh I. Measuring HER-2 in Breast Cancer: Immunohistochemistry, FISH, or ELISA? Am J Clin Pathol. 2002; 117(Suppl 1):S26-S35. Available at: https://www.researchgate.net/profile/I_Tien_Yeh/publication/231585094_Measuring_HER-2_in_breast_cancer._Immunohistochemistry_FISH_or_ELISA/links/55bfedf108aec0e5f4476c05.pdf. Accessed May 15, 2016.